诺和诺德(NVO.US)涨近6% 因竞争对手礼来(LLY.US)口服减肥药效果不及预期

Core Viewpoint - Novo Nordisk's stock price increased by nearly 6% to $47.99 following news about a competitor's drug performance [1] Group 1: Company Performance - Novo Nordisk's stock price rose significantly, indicating positive market sentiment towards the company [1] - The competitor Eli Lilly's first oral GLP-1 drug, Orforglipron, achieved an average weight loss of 11.2%, which was below the expected range of 13% to 15% or more [1] Group 2: Market Reaction - The market reacted positively to Novo Nordisk's stock, reflecting investor confidence in its products compared to competitors [1] - The underperformance of Eli Lilly's drug may create a competitive advantage for Novo Nordisk in the GLP-1 market [1]